IPO Timeline
Broker Results (T-2)
2023-09-21
Some brokers release in afternoon
Grey Market (T-1)
2023-09-22
Afternoon
HKEX Allotment (T-1)
2023-09-22
Evening
Registrar Allotment (T-1)
2023-09-22
Evening
Listing Day (T)
2023-09-25
First day of trading
Company Overview
| Stock Name | 友芝友生物－Ｂ |
|---|---|
| Stock Code | 02496 |
| Company Full Name | 友芝友生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家致力于開發用于治療癌癥相關并發癥、癌癥及老年性眼科疾病的BsAb療法的生物技術公司。 |
| Listing Date | 2023-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國湖北省武漢市東湖新技術開發區高新大道666號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.yzybio.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 16.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 59.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 17,603,200 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,200 |
| 2 lots | 400 | HK$ 6,400 |
| 3 lots | 600 | HK$ 9,600 |
| 4 lots | 800 | HK$ 12,800 |
| 5 lots | 1,000 | HK$ 16,000 |
| 6 lots | 1,200 | HK$ 19,200 |
| 7 lots | 1,400 | HK$ 22,400 |
| 8 lots | 1,600 | HK$ 25,600 |
| 9 lots | 1,800 | HK$ 28,800 |
| 10 lots | 2,000 | HK$ 32,000 |
| 15 lots | 3,000 | HK$ 48,000 |
| 20 lots | 4,000 | HK$ 64,000 |
| 25 lots | 5,000 | HK$ 80,000 |
| 30 lots | 6,000 | HK$ 96,000 |
| 35 lots | 7,000 | HK$ 112,000 |
| 40 lots | 8,000 | HK$ 128,000 |
| 45 lots | 9,000 | HK$ 144,000 |
| 50 lots | 10,000 | HK$ 160,000 |
| 75 lots | 15,000 | HK$ 240,000 |
| 100 lots | 20,000 | HK$ 320,000 |
| 125 lots | 25,000 | HK$ 400,000 |
| 150 lots | 30,000 | HK$ 480,000 |
| 175 lots | 35,000 | HK$ 560,000 |
| 200 lots | 40,000 | HK$ 640,000 |
| 250 lots | 50,000 | HK$ 800,000 |
| 300 lots | 60,000 | HK$ 960,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 16.0 |
|---|---|
| First Day Open | HK$ 16.4 |
| First Day Change | -67.75% |
| First Day Volume | 1519600.0 |
| First Day Turnover | 24912300.0 |
Use of Proceeds
| Use of Proceeds | 1、約80%或約97.1百萬港元將用作核心產品M701計劃進行的臨床試驗、擬備注冊備案文件及商業化推出計劃； 2、約12%或14.6百萬港元將用作Y101D計劃進行的臨床試驗； 3、約8%或9.7百萬港元將用作營運資金和一般公司用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中信建投（国际）融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投（国际）融资有限公司 CE BAU112
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
Joint Bookrunners (6)
中信建投（国际）融资有限公司 CE BAU112
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
中银国际亚洲有限公司 CE AET863
天风国际证券与期货有限公司 CE BAV573
中国银河国际证券（香港）有限公司 CE AXM459
Joint Lead Managers (8)
中信建投（国际）融资有限公司 CE BAU112
国泰君安证券（香港）有限公司 CE ABY236
建银国际金融有限公司 CE AJO225
中银国际亚洲有限公司 CE AET863
天风国际证券与期货有限公司 CE BAV573
中国银河国际证券（香港）有限公司 CE AXM459
利弗莫尔证券有限公司 CE BJN764
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 成都朴华凯智生物科技有限公司 | 21,481,600 HKD | — | 12.20% | — | 6 months | 2024-03-25 |
| 2 | 武汉光谷健康产业投资有限公司 | 42,976,000 HKD | — | 24.42% | — | 6 months | 2024-03-25 |
| 3 | 武汉市楚兴友瑞大健康产业投资基金合伙企业(有限合伙) | 39,763,200 HKD | — | 22.59% | — | 6 months | 2024-03-25 |
Directors & Management
| Chairman | Zhou Pengfei |
|---|---|
| Company Secretary | 鄭建華;賴天恩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 袁謙(10.57%);武漢才智投資管理合伙企業(有限合伙)(8.70%);周宏峰(5.28%) |
|---|
Subscription Tiers
IPO Timeline
